The conclusion by the UK’s National Institute for Health and Clinical Excellence (NICE) to reject Bristol-Myers Squibb’s new melanoma drug Yervoy has been greeted with disappointment by the company and patient groups. In a provisional draft guidance published earlier today, NICE decided against recommending payment by the UK’s National Health Service (NHS) of Yervoy (ipilimumab)
The Bristol-Myers Squibb Foundation yesterday announced a partnership with the World Health Organization’s (WHO) Stop TB Department for a two-year pilot initiative to strengthen community based prevention, care and control of tuberculosis (TB) including co-infection with HIV in South Africa, Tanzania, Kenya, Ethiopia and Democratic Republic of the Congo. These countries represented more than 13%
Bristol-Myers Squibb (BMS) Company has completed its previously announced acquisition of Amira Pharmaceuticals, a privately held small-molecule pharmaceutical company, focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. As a result of the transaction, Amira Pharmaceuticals has now become a wholly-owned subsidiary of Bristol-Myers Squibb. The acquisition of
NICE (the National Institute for Health and Clinical Excellence) has issued final guidance rejecting the use of Bristol-Myers Squibb’s Orencia (abatacept) as a second-line treatment for rheumatoid arthritis (RA). The guidance says that the use of Orencia is not recommended in combination with methotrexate for treating RA in adults whose disease has responded inadequately to
GNS Healthcare have announced a collaboration with Bristol-Myers Squibb (BMS) to provide a computer model that can support virtual clinical trials in the field of immuno-inflammation. No financial terms were disclosed on the tie-up, under which GNS will take clinical and molecular information from a BMS clinical trial and will use its supercomputer-driven REFS (reverse-engineering
Bristol-Myers Squibb has hit the acquisition trail again and is buying privately held Amira Pharmaceuticals in a deal that could be worth $475 million to the inflammatory and fibrotic diseases specialist. Under the terms of the agreement, B-MS is shelling out $325 million in an upfront fee and may make additional milestone payments totalling $150
